Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.
Oral and/or intestinal mucositis is a severe complication of hematopoietic SCT. Keratinocyte growth factor (KGF) has proven activity in the prevention of oral mucositis. We examined the efficacy of KGF in the prevention of intestinal mucositis. From January 2006 until December 2007, 35 consecutive patients underwent autologous SCT (auto-SCT) in our institution. A total of 15 consecutive patients who underwent auto-SCT from March 2007 to December 2007 received KGF for the prevention of mucositis and were included in the study group A, whereas 20 consecutive patients treated from January 2006 to March 2007, were included in the historical control group B. Oral and intestinal mucositis were significantly less severe in group A (P=0.002 and P<0.001, respectively). These results were confirmed with the use of video-capsule endoscopy. Patients in group A had a significantly lower incidence of neutropenic fever (P=0.026). Severe intestinal mucositis was significantly associated with a higher incidence of documented infections too (P=0.019). KGF is effective in the prevention of intestinal mucositis in patients undergoing auto-SCT. Patients with severe intestinal mucositis run a higher risk to develop infections.
Tsirigotis
P
P
Haematology Unit, Second Department of Internal Medicine-Propaedeutic, Attikon University General Hospital, Medical School, University of Athens, Athens, Greece. tsiris1@otenet.gr
Triantafyllou
K
K
Girkas
K
K
Giannopoulou
V
V
Ioannidou
E
E
Chondropoulos
S
S
Kalli
T
T
Papaxoinis
G
G
Pappa
V
V
Papageorgiou
E
E
Economopoulos
T
T
Ladas
S D
SD
Dervenoulas
J
J
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D053704:Capsule Endoscopy; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000008:administration & dosage*; D019337:Hematologic Neoplasms / Q000473:pathology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007410:Intestinal Diseases / Q000473:pathology / Q000517:prevention & control; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D052016:Mucositis / Q000473:pathology* / Q000517:prevention & control*; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000009:adverse effects; D014182:Transplantation, Autologous
D003561:Cytarabine; D051523:Fibroblast Growth Factor 7; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine